As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

It wants to get ahead of competitors such as BMS, Merck, Pfizer ... The interaction with GSK goes deeper, with Novartis and GSK announcing a merger of their OTC divisions to create a new joint ...

It was the third largest pharma takeover of all time, surpassed only by the merger of Glaxo Wellcome and SmithKline Beecham in 2000 and Pfizer’s buyout of Warner Lambert. Those deals were worth ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month ... which include GSK’s Haleon spinout and Proctor & Gamble as well as the larger market.

The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Consumer Health restructuring The merger of GlaxoSmithKline and Pfizer is dragging on sales—up 1 percent in 2019—as the businesses streamline. This compares with a Glaxo consumer ...

It is generally well appreciated that the pharmaceutical industry has entered a period of revenue underperformance. However, the severity of this underperformance, even when measured against ...

Parke-Davis (India) in the near future is unlikely to get five major products which Glaxo Wellcome worldwide ... The operational merger between Pfizer and Parke-Davis has been completed and ...

Moderna, Pfizer, and BioNTech are also developing ... and 11% have gotten this year’s vaccine.GlaxoSmithKline sued Moderna in ...

A total of 739 deals were completed so far this year representing a decrease of just under 21 per cent compared to last year.